Evidence map›Paper›PMID 40828444›Full record

Observational studyInternal and emergency medicine2026

FIB-4, a surrogate marker of liver fibrosis, predicts mortality and adverse events after acute myocardial ınfarction.

Mehmet Gorur, Salim Satar, Selen Acehan, Muge Gulen, Kadir Nigiz, Sarper Sevdımbas

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mehmet GorurEmergency Medicine Clinic, Adana City Training and Research Hospital, Health Sciences University, Mithat Ozhan Avenue, 01370, Yuregir, Adana, Turkey.ORCID http://orcid.org/0009-0007-6159-6476
Salim SatarEmergency Medicine Clinic, Adana City Training and Research Hospital, Health Sciences University, Mithat Ozhan Avenue, 01370, Yuregir, Adana, Turkey.ORCID http://orcid.org/0000-0001-6080-4287
Selen AcehanEmergency Medicine Clinic, Adana City Training and Research Hospital, Health Sciences University, Mithat Ozhan Avenue, 01370, Yuregir, Adana, Turkey. selenacehan@hotmail.com.ORCID http://orcid.org/0000-0003-4390-6593
Muge GulenEmergency Medicine Clinic, Adana City Training and Research Hospital, Health Sciences University, Mithat Ozhan Avenue, 01370, Yuregir, Adana, Turkey.ORCID http://orcid.org/0000-0002-5080-3501
Kadir NigizEmergency Medicine Clinic, Adana City Training and Research Hospital, Health Sciences University, Mithat Ozhan Avenue, 01370, Yuregir, Adana, Turkey.ORCID http://orcid.org/0009-0000-7067-6370
Sarper SevdımbasEmergency Medicine Clinic, Adana City Training and Research Hospital, Health Sciences University, Mithat Ozhan Avenue, 01370, Yuregir, Adana, Turkey.ORCID http://orcid.org/0000-0002-0271-9305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Fibrosis-4 (FIB-4) score is a simple, non-invasive index originally developed to assess liver fibrosis. Recently, it has gained attention as a potential prognostic marker in cardiovascular diseases. This study aimed to evaluate whether the FIB-4 score, independent of its role in liver assessment, can predict short-term mortality and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI) undergoing coronary angiography (CAG) in the emergency department (ED). In this prospective observational study, 1017 patients diagnosed with AMI and treated with CAG between May 1, 2023, and February 29, 2024, were included. Patients were stratified into three groups based on FIB-4 score: low (< 1.45), intermediate (1.45-3.25), and high (> 3.25). Clinical and laboratory data, HEART scores, angiographic findings, in-hospital and 30-day outcomes were compared across groups. Patients with FIB-4 > 3.25 exhibited significantly higher rates of ST-elevation myocardial infarction (60.2%), hypertension (64%), diabetes mellitus (47.5%), atrial fibrillation (11%), and ventricular tachycardia (2.1%) (all p < 0.01). In-hospital mortality (14.4%), 30-day mortality (19.9%), and MACE (24.8%) were significantly elevated in this group (p < 0.001). Multivariate analysis identified FIB-4 > 3.25 (OR 3.816; p = 0.001), HEART score (OR 1.161; p = 0.013), and hemoglobin (OR 0.873; p = 0.038) as independent predictors of mortality. ROC analysis revealed moderate discriminative performance for FIB-4 (AUC: 0.693) and HEART score (AUC: 0.766). Elevated FIB-4 scores are independently associated with increased short-term mortality and adverse cardiovascular outcomes in AMI patients undergoing CAG. Beyond its traditional role in liver disease, the FIB-4 score may serve as a practical, non-invasive biomarker for early cardiovascular risk stratification in patients presenting to the ED with acute myocardial infarction.

Indexed as

BiomarkersLiver CirrhosisMyocardial InfarctionAgedCoronary AngiographyFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisProspective StudiesROC CurveBiomarkersAcute myocardial infarctionEmergency departmentFIB-4 scoreLiver fibrosisMACEMortalityRisk stratification

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.